ImmunoGen, Inc.
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase…
Biotechnology
US, Waltham [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q2 | Q3 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | -10.44 | 5.47 | 6.10 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | -92.02 | -17.41 | 218.16 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q2 | Q3 | Δ in % | |
|---|---|---|---|---|
| Book Value | 4.81 | 1.95 | 1.86 | |
| Cash | -3.02 | 2.11 | 2.17 | |
| Capex | -1490.16 | < 0.005 | < 0.005 | |
| Free Cash Flow | -98.06 | < 0.005 | -0.25 | |
| Revenue | 24.95 | 0.39 | 0.32 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q2 | Q3 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | -0.82 | 0.98 | 0.99 | |
| Operating Margin | 354.25 | 0.23 | -0.05 | |
| ROA | 528.93 | 0.04 | < 0.005 | |
| ROE | 532.63 | 0.05 | < 0.005 | |
| ROIC | 381.05 | 0.04 | < 0.005 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of IMGN is permitted for members.
5
Growth
The "Growth Entry" for the Focus of IMGN is permitted for members.
6
Leverage & Liquidity